1. Most patients will not die from follicularlymphoma, and that's very reassuring.
大部分患者将不会死于滤泡性淋巴瘤，这是非常肯定的。
来自互联网
2. We describe the clinicopathologic features of 88 cases of CD5+ follicularlymphoma (53 men, 35 women;
作者描述88例CD5+的滤泡性淋巴瘤临床病理学特征（男性53例，女性35例；
来自互联网
3. Objective To discuss the differential diagnosis between tumor-like follicular hyperplasia and follicularlymphoma.
目的讨论淋巴滤泡瘤样增生与滤泡性淋巴瘤的鉴别诊断。
来自互联网
4. The PI3K deltainhibitor idelalisib (Zydelig) and the BTK inhibitor ibrutinib (Imbruvica) have shown promise for patients with relapsed follicularlymphoma.
5. INTERPRETATION: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicularlymphoma significantly improves PFS.
6. If your disease does not respond to initial treatment, your treatment options are detailed below under Treatment of Recurrent or Refractory FollicularLymphoma.
如果你的肿瘤对初始治疗无效，你的治疗选择详见复发或难治性滤泡淋巴瘤的治疗部分。
来自互联网
7. In addition to representing a potential biomarker, the existence of cells with defective BCR signaling may provide new targets against follicularlymphoma. -jcl.
除了代表潜在的生物标记物外，伴有缺陷BCR信号的细胞存在可提供滤泡性淋巴瘤新的靶点。
来自互联网
8. In a small 30-patient study, pidilizumabplus rituximab demonstrated an ORR of 66% in relapsed follicularlymphoma, which primarily consisted of complete responses.
9. Additionally, a phase II study is looking at the combination of rituximab and pembrolizumab (Keytruda) for patients with relapsed follicularlymphoma (NCT02446457).
此外，一项二期研究将利妥昔单抗和pembrolizumab联合来治疗复发的滤泡性淋巴瘤。
来自互联网
10. Watch and wait (WAW) is a common approach for asymptomatic, advanced stage follicularlymphoma (FL), but single-agent rituximab is an alternative for these patients.
观察等待是无症状的晚期滤泡性淋巴瘤常用的策略，但是对于这些患者来说美罗华单药治疗也是一个选项。
来自互联网
11. ObjectiveTo assess the effectiveness and safety of high-dose chemotherapy following autologous stem cell transplantation in first-line treatment of follicularlymphoma.
目的系统评价大剂量化疗后自体干细胞移植一线治疗滤泡性淋巴瘤的临床疗效与安全性。
来自互联网
12. The phase II CheckMate-140 trial is exploring nivolumab (Opdivo) for patients with follicularlymphoma following progression on a CD20 antibody and an alkylating agent (NCT02038946).
13. We assessed the potential benefit of 2 years of rituximab maintenance after first-line treatment in patients with follicularlymphoma receiving a rituximab plus chemotherapy regimen.
我们的研究旨在评价利妥昔单抗加化疗一线治疗的滤泡性淋巴瘤患者使用利妥昔单抗维持治疗2年的疗效。
来自互联网
14. "These responses are meaningful, not as dramatic as we have seen in Hodgkin's, but it is meaningful," said Leonard. "The question is, 'can you develop this drug in follicularlymphoma?"
15. In late February 2016, the FDA approved the anti-CD20 agent obinutuzumab(Gazyva) in combination with bendamustine for patients with follicularlymphoma following rituximab-based therapy.
16. The cancer vaccines rely on a biological quirk of follicular B-cell lymphoma, which is a type of non-Hodgkin's lymphoma.
滤泡性B细胞淋巴瘤是一种非霍奇金淋巴瘤，肿瘤疫苗是治疗是根据肿瘤细胞的生物学特殊性。
来自互联网
17. Objective To investigate the morphological features and immunophenotype of unspecified peripheral t cell lymphoma with distinct lymphoid follicular growth pattern.
目的探讨伴有明显淋巴滤泡增生的非特指外周T细胞淋巴瘤的形态学特点和免疫表型。
来自互联网
18. Objective To investigate the morphological features and immunophenotype of unspecified peripheral t cell lymphoma with distinct lymphoid follicular growth pattern.
